Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen

C. E. Touloukian, W. W. Leitner, P. F. Robbins, S. A. Rosenberg, N. P. Restifo

Research output: Contribution to journalArticle

Abstract

To identify novel, tumor-specific target antigens for vaccine development, we studied immune responses to P. polypeptide, an Mr 110,000 integral melanosomal membrane protein associated with the Prader-Willi syndrome. Together with expressed sequence tag (EST) and serial analyses of gene expression (SAGE) library analyses, reverse transcription-PCR and Northern blotting verified that P. polypeptide expression was limited to melanoma and melanocytes. A single dominant epitope corresponding to positions 427-435 (IMLCLIAAV) was identified using allele-specific epitope forecasting combined with work in HLA-A*0201/Kb transgenic mice. This epitope was then used to generate de novo human P. polypeptide-specific CD8+ T cells capable of recognizing P. polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P. polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines.

Original languageEnglish (US)
Pages (from-to)8100-8104
Number of pages5
JournalCancer Research
Volume61
Issue number22
StatePublished - Nov 15 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen'. Together they form a unique fingerprint.

  • Cite this

    Touloukian, C. E., Leitner, W. W., Robbins, P. F., Rosenberg, S. A., & Restifo, N. P. (2001). Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen. Cancer Research, 61(22), 8100-8104.